Treatment of cardiovascular disease during the Covid-19 pandemic

23 April 2020 (Last Updated April 23rd, 2020 12:25)

As Covid-19 moves through the global population at an alarming rate, with over two million confirmed global cases since December, data-based research and further understanding of the virus is paramount to improving the preparation and management of patients and the general population.

Moreover, it is vital to understand the at-risk population to minimise the burden on global healthcare structures and maintain high-quality patient care. Cardiovascular disease (CVD) has been found to be a risk factor for patients and those with CVD are therefore categorised as a vulnerable patient group. However, new research has shown that although those with CVD are at risk, cardiac injury can occur in those with confirmed Covid-19 and no previous cardiovascular (CV) risk. This will increase the use of and the demand for various CV treatments as patients are treated symptomatically and potentially longer-term if the myocardium effects are long-lasting.

Click here to read more from the full article.